Nifedipine Sustained-Release (SR): Clinical Overview
Nifedipine SR is an effective once-daily calcium channel blocker indicated for hypertension and chronic stable angina, with dosing typically starting at 30 mg daily and titrating up to 60-90 mg daily based on blood pressure response.
Indications
Nifedipine SR is indicated for:
- Hypertension (primary indication) 1, 2, 3
- Chronic stable angina 1, 4
- Isolated systolic hypertension in elderly patients 5, 6
The sustained-release formulation allows once-daily dosing, improving patient compliance compared to immediate-release preparations 7, 8.
Dosing Regimen
Starting dose: 30 mg once daily 9, 10
Titration: Increase to 60 mg once daily if blood pressure control is inadequate after 7-14 days. Maximum dose is 90 mg daily 9, 7
Timing: Can be administered without regard to meals, though high-fat meals may slightly reduce absorption (approximately 4.8%) and accelerate time to peak concentration 11. The sustained-release formulation provides consistent 24-hour blood pressure control 7, 10.
Special populations:
- Elderly patients: Start at lower end of dosing range due to increased drug exposure from age-related decreased baroreceptor response 12
- Pregnancy/Postpartum: Immediate-release nifedipine 10-20 mg orally can be used for acute hypertensive crises (onset 5-10 minutes), with maximum daily dose of 180 mg 13, 3. Extended-release formulations: 30 mg daily starting dose, maximum 120 mg daily 13
- Pediatric use: Not routinely recommended; requires specialized formulations and dosing strategies 14
Contraindications
Absolute contraindications:
- Cardiogenic shock 9
- Known hypersensitivity to nifedipine or any component 9
- Concomitant use with strong CYP3A4 inducers (e.g., rifampin) 9
- Pregnancy (for spironolactone combinations, not nifedipine itself) 3
Relative contraindications and cautions:
- Severe left ventricular dysfunction or heart failure: Avoid in patients with pulmonary edema or evidence of severe LV dysfunction 4, 15. Calcium channel blockers may precipitate or worsen heart failure 12
- Acute coronary syndromes: Immediate-release nifedipine should NEVER be used in UA/NSTEMI or acute MI without concomitant beta-blocker therapy due to increased mortality risk 1, 2, 4, 16
- Severe aortic stenosis: Use with caution
- Elderly patients ≥75 years with chronic constipation: Consider alternative agents 12
Common Adverse Effects
The most frequent adverse effects are dose-related and primarily due to peripheral vasodilation 9:
Very common (>10%):
- Peripheral edema: 18% at 30 mg daily, 22% at 60 mg daily, 29% at 90 mg daily (vs. 10% placebo) 9
Common (3-10%):
Less common but important (<3%):
- Hypotension (particularly with immediate-release formulations) 12, 17
- Reflex tachycardia (less common with sustained-release vs. immediate-release) 8
- Gingival hyperplasia (with chronic use) 9
Serious but rare:
Critical Clinical Pearls
Avoid immediate-release nifedipine: Short-acting nifedipine capsules should NOT be prescribed due to precipitous blood pressure drops, reflex tachycardia, and increased cardiovascular events 12, 2, 5, 4, 15, 16. This is a Class III (Harm) recommendation in multiple guidelines.
Monitoring requirements:
- Blood pressure monitoring (target <140/90 mmHg for most patients, <130/80 mmHg for diabetes) 2, 3
- Assess for peripheral edema at each visit 12
- Monitor for signs of heart failure (particularly in elderly or those with pre-existing LV dysfunction) 12
Drug interactions:
- Strong CYP3A4 inducers (rifampin) significantly reduce efficacy 9
- Avoid combination with magnesium sulfate in pregnancy due to risk of severe hypotension 17
- Use caution when combining with beta-blockers in patients with LV dysfunction 4, 16
Pregnancy considerations: Nifedipine (immediate-release for acute management, extended-release for maintenance) is considered safe and effective for hypertensive disorders of pregnancy, with minimal maternal or fetal side effects 13, 17, 3, 18. It is compatible with breastfeeding (relative infant dose 2.3-3.4%) 13.